Vivek Subbiah is the Chief of Early-Phase Drug Development Across the Sarah Cannon Research Institute’s research network, one of the world’s leading oncology research organizations conducting clinical trials.  He oversees the drug development units and is leading the expansion of early-phase capabilities and programs across the organization’s growing research network of physicians at more than 250 locations across the United States. Previously he was an Associate Professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center.  He was also the Clinical Medical Director, Division of Cancer Medicine, a role in which he oversaw both the outpatient and inpatient clinical care delivery operations for the Phase I program.